Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
If a federal or state-level rebate contract for Betamethason and Fusidinsäure is concluded, the open-house agreements a...
Submission rules are detailed: paper copies must be submitted in duplicate, and electronic submissions require qualifie...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Non-exclusive pharmaceutical rebate agreements for Betamethason and Fusidinsäure (ATC D07CC01) under § 130a Abs. 8 SGB V.
- Open-house model: all qualified pharmaceutical companies may sign identical, non-negotiable rebate contracts.
Show full summary
Open-house model for non-exclusive pharmaceutical rebate agreements on Betamethason and Fusidinsäure (ATC D07CC01) with AOK Bayern. All qualified pharmaceutical companies may join. Contract runs from 01.06.2025 to 31.05.2027, with rolling entry. No estimated value provided. No award criteria; eligibility based solely on a signed self-declaration of reliability.
Risks
If a federal or state-level rebate contract for Betamethason and Fusidinsäure is concluded, the open-house agreements a...
Submission rules are detailed: paper copies must be submitted in duplicate, and electronic submissions require qualifie...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Eligibility: Only pharmaceutical companies (pharmazeutische Unternehmen) may participate.
Administrative
- Submission of completed and signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed self-declaration of reliability.
- Submission in paper form (2 copies) or electronically with qualified electronic signature.
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01
Non-exclusive rebate agreements for pharmaceutical products with active ingredients Betamethason and Fusidinsäure, ATC code D07CC01. Place of performance: Bavaria, Germany. Contract type: supplies. Framework agreement with no maximum value stated.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 250356-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
If a federal or state-level rebate contract for Betamethason and Fusidinsäure is concluded, the open-house agreements a...
Submission rules are detailed: paper copies must be submitted in duplicate, and electronic submissions require qualifie...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications